University of Tennessee Health Science Center

Dental Care Alliance Welcomes Atlanta Center for Cosmetic Dentistry of Atlanta, GA

Retrieved on: 
Wednesday, November 8, 2023
USA Today, Medical college, Outline of health sciences, Extreme Makeover, United States Department of the Air Force, Brigham Young University, Business development, Omicron Kappa Upsilon, American Academy of Cosmetic Dentistry, Crown, Family medicine, Time (magazine), DCA, Accreditation, Health, Fellow, Dental care, The Doctors, The Wall Street Journal, Growth, ABC, Dentist, Organic, Fox News, University, CBS, ACCD, American Academy, Partnership, Science education, InStyle, Eye, University of Tennessee Health Science Center, Air force, AACD, CNN, Cosmetic dentistry, Mississippi State University, University of Kentucky College of Dentistry, Patient, Philosophy, University of Mississippi School of Engineering, Dentistry, Science, Glamour

SARASOTA, Fla., Nov. 8, 2023 /PRNewswire-PRWeb/ -- Dental Care Alliance (DCA) is pleased to welcome the esteemed Atlanta Center for Cosmetic Dentistry, a four-doctor single location cosmetic practice located in Atlanta, GA. Atlanta Center for Cosmetic Dentistry was founded by Dr. Debra Gray King and has been helping Atlanta smile a little brighter for over 30 years!

Key Points: 
  • Dental Care Alliance (DCA) is pleased to welcome the esteemed Atlanta Center for Cosmetic Dentistry, a four-doctor single location cosmetic practice located in Atlanta, GA. Atlanta Center for Cosmetic Dentistry was founded by Dr. Debra Gray King and has been helping Atlanta smile a little brighter for over 30 years!
  • SARASOTA, Fla., Nov. 8, 2023 /PRNewswire-PRWeb/ -- Dental Care Alliance (DCA) is pleased to welcome the esteemed Atlanta Center for Cosmetic Dentistry, a four-doctor single location cosmetic practice located in Atlanta, GA. Atlanta Center for Cosmetic Dentistry was founded by Dr. Debra Gray King and has been helping Atlanta smile a little brighter for over 30 years!
  • Atlanta Center for Cosmetic Dentistry offers a full range of cosmetic, restorative, and general dentistry services including porcelain veneers, prepless ultra-thin veneers, cosmetic bonding, teeth whitening, gum shaping, full mouth construction, anti-aging dentistry, Invisalign, implants, bridges, and crowns; all with an eye for beautiful natural results.
  • Atlanta Center for Cosmetic Dentistry dentists are members of the American Academy of Cosmetic Dentistry and are passionate about creating beautiful smiles.

inTRAvent Medical Partners Names Dr. Kevin Foley Chief Innovation Officer

Retrieved on: 
Tuesday, October 17, 2023
Technology, Surgery, Medical Devices, Hospitals, Biotechnology, Health, Robotics, General Health, Artificial Intelligence, Remi, Knowledge, Barr v. American Assn. of Political Consultants, Inc., Neuro, Brain, Standard of care, MD, Caregiver, Safety, University, Hospice and palliative medicine, EVD, Congress of Neurological Surgeons, Anatomy, University of Tennessee Health Science Center, Patient, FDA, Artificial intelligence, 2D, CIO, ICU, Pathology, Biomedical engineering, Hematoma, Pharmaceutical industry, Nursing, Medical imaging, Management, Neurosurgery

inTRAvent Medical Partners LP , a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced the appointment of Kevin Foley, MD, in the newly created role of Chief Innovation Officer (CIO).

Key Points: 
  • inTRAvent Medical Partners LP , a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced the appointment of Kevin Foley, MD, in the newly created role of Chief Innovation Officer (CIO).
  • Dr. Foley is a pioneer in neurosurgical navigation, with more than 175 U.S. patents to his name.
  • He serves on the boards of directors for several medical device and biologics companies, and is a recipient of the Cushing Award for Technical Excellence and Innovation in Neurosurgery from the American Assn.
  • We anticipate that his innovative spirit and visionary leadership will be pivotal to achieving our mission: enhancing the safety and precision of bedside neurosurgical procedures,” said inTRAvent co-founder and Chief Medical Officer Dr. Will Hazard.

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Probability, Cancer, LRA, Lupus nephritis, Inflammation, Lupus Research Alliance, Cell, Viral, University, Autoimmune disease, University of Tennessee Health Science Center, Therapy, Education, Kidney, Lupus, CAR, Research, NK, Patient, Pharmaceutical industry

Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of top academic centers throughout North America.

Key Points: 
  • Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of top academic centers throughout North America.
  • NKX109, an allogenic CD19-directed CAR NK cell therapy, is currently being studied in oncology, but this is the first time the therapy will be evaluated in lupus nephritis, an inflammation of the kidney caused by lupus.
  • "Lupus Therapeutics is pleased to collaborate with innovative biopharmaceutical companies such as Nkarta to accelerate the clinical evaluation of cell therapies as they advance through development.
  • Lupus Therapeutics, and Lupus Research Alliance as a whole, are leading the way to fundamental understanding, clinical development and evaluation and the education about cell therapy for the treatment of lupus.

Paylocity Recognizes Outstanding Achievements in Modern HCM with its Inaugural Elevate Awards

Retrieved on: 
Monday, October 9, 2023
Diagnosis, SMS, Smoke, Ear, ServiceMaster, Machine learning, Common, HR, Elevate, Organization, AI, University, University of Tennessee Health Science Center, HCM, Maintenance, United States at the Olympics, The arts, Desert dry wash, Nose, Timesheet, Paylocity, Farm, Water, Interior design, Management, Nursing, Operation

“This inaugural class of Elevate Award winners embodies the best attributes of Paylocity clients,” said Kathy Ross, Paylocity Senior Vice President of Operations.

Key Points: 
  • “This inaugural class of Elevate Award winners embodies the best attributes of Paylocity clients,” said Kathy Ross, Paylocity Senior Vice President of Operations.
  • The Elevate Awards honor those companies that have demonstrated business excellence in how they use modern HCM technology.
  • The submission process for the Elevate awards required nominees to share critical HR insights and outcomes, with specific examples of how using Paylocity’s HCM platform modernized their work.
  • Throughout the conference, employee engagement and culture building were cited Elevate attendees as vital components of organizational success.

AdhereHealth CEO to Lead the University of Tennessee Health Science Center's Discussions on Medication Adherence and Achieving the Quintuple Aim of Healthcare

Retrieved on: 
Thursday, September 7, 2023
IPPE, Partnership, University, UT, College, University of Tennessee Health Science Center, UTHSC, Medicine, SDOH, COP, Medicare, Pharmacist, Death, Student, Daniel K. Inouye College of Pharmacy, Patient, Physician, Knowledge, Health, Pharmaceutical industry, Nursing, Pharmacy

NASHVILLE, Tenn., Sept. 7, 2023 /PRNewswire/ -- AdhereHealth, a healthcare technology leader in medication adherence insights and health outcomes, announced today that CEO, Jason Rose, will join the University of Tennessee Health Science Center (UTHSC) College of Pharmacy's (COP) continuing education program to discuss medication adherence and its impact on the quintuple aim of healthcare. The series of live virtual events will take place on September 7, October 5 and November 2, 2023.

Key Points: 
  • The series of live virtual events will take place on September 7, October 5 and November 2, 2023.
  • "Poor medication adherence is tied to approximately half of all treatment failures, more than 125,000 avoidable deaths, and more than half a trillion dollars in wasted spending each year," said Jason Rose, CEO of AdhereHealth.
  • To achieve value-based care goals and improve patient experiences, health plans need better tools to address medication adherence at its source."
  • To learn more about AdhereHealth solutions and the benefits they deliver for health plans, visit Adherehealth.com.

Phil Wenk to Retire as CEO of Delta Dental of Tennessee and become President of the Company’s Charitable Foundation; Jeff Ballard Named Successor

Retrieved on: 
Tuesday, August 29, 2023
Professional Services, Philanthropy, Health, Insurance, Health Insurance, Dental, Foundation, University, Alumni, UTHSC, Ohio State University College of Dentistry, American City Business Journals, Multimedia, Music City Bowl, Chairperson, Organization, American Cancer Society, Retirement, Magazines.com, CPA, University of Tennessee Health Science Center, CFO, Growth, Delta Dental, Middle Tennessee State University, MTSU, Franklin, Management, Nursing, Dentistry

Delta Dental of Tennessee (Delta Dental) today announced that Dr. Phil Wenk will retire as chief executive officer (CEO) on December 31, 2023.

Key Points: 
  • Delta Dental of Tennessee (Delta Dental) today announced that Dr. Phil Wenk will retire as chief executive officer (CEO) on December 31, 2023.
  • Jeff Ballard, CPA, current president and CFO of Delta Dental, will succeed Wenk and become president and CEO effective January 1, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20230829965953/en/
    Jeff Ballard (left), president and CFO of Delta Dental, will succeed Dr. Phil Wenk (right) and become president and CEO effective January 1, 2024.
  • (Photo: Business Wire)
    Dr. Wenk joined Delta Dental in 1997 after practicing dentistry for 20 years and has led the company as President and CEO since 2000.

MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

Retrieved on: 
Monday, July 31, 2023
Surgery, Medical Devices, Neurology, Hospitals, Clinical Trials, Cardiology, Biotechnology, Radiology, Health, Neuroradiology, Bleeding, Aneurysm, Clinical trial, GCP, SL, Multimedia, Neck, Terumo, Patient, Physician, University, WEB, University of Tennessee Health Science Center, Radiation exposure, Safety, Pharmaceutical industry, Medical imaging, Neurosurgery

With this five-year clinical trial data just recently published, WEB is the most well studied intrasaccular device available in the marketplace today, with 7 good clinical practice (GCP) studies and over 200 peer-reviewed publications.

Key Points: 
  • With this five-year clinical trial data just recently published, WEB is the most well studied intrasaccular device available in the marketplace today, with 7 good clinical practice (GCP) studies and over 200 peer-reviewed publications.
  • WEB is also now available in two new sizes (SL 6x2 and SL 7x2), continuing to allow for the treatment of different sizes and shapes of aneurysms.
  • Additionally, the WEB device provides proven, long-term durability with its five-year follow-up results demonstrating long-term safety and effectiveness and is the only 17-system compatible intrasaccular flow disruptor.
  • At this time, there is no device that has been shown to be safer for aneurysm patients than WEB.

Honoring a patron painter and charitable NBA coach at St. Jude Spirit of the Dream

Retrieved on: 
Saturday, July 1, 2023
Celebrity, Oncology, Philanthropy, Basketball, Hospitals, Sports, Children, Family, Science, Arts, Museums, Entertainment, Other Philanthropy, Consumer, Health, Research, Nexus, Grizzlies, Human, LHC, MFA, Travel, Housing, Food, International, Brooklyn Museum, University, University of Tennessee Health Science Center, The Guest House, Harvard University, Brooklyn, National Basketball Association, Parent, Hunter College, St. Joseph's Hospital, Morehouse College, Dream, ALSAC, African, Woman, Multimedia, History, NBA draft, Dallas Museum of Art, Student, Solomon R. Guggenheim, 1976–77 Portland Trail Blazers season, Patient, NBA, Child, NBA Finals, Hospital, Book, African Americans, Nursing, Memphis Grizzlies, Cooper Union, Jude the Apostle, Art

St. Jude Spirit of the Dream presented by W&T Contracting Corporation has selected this year’s honorees for its highest accolade: the St. Jude Spirit of the Dream award.

Key Points: 
  • St. Jude Spirit of the Dream presented by W&T Contracting Corporation has selected this year’s honorees for its highest accolade: the St. Jude Spirit of the Dream award.
  • View the full release here: https://www.businesswire.com/news/home/20230628223214/en/
    International artist Derek Fordjour and former National Basketball Association (NBA) player and Memphis Grizzlies coach and philanthropist, Lionel Hollins, will be honored at the eighth annual St. Jude Spirit of the Dream.
  • (Photo: Business Wire)
    The eighth annual St. Jude Spirit of the Dream will honor international artist Derek Fordjour and former National Basketball Association (NBA) player and Memphis Grizzlies coach and philanthropist, Lionel Hollins.
  • Dr. Rudolph Jackson , (St. Jude Legacy Award) one of the first Black doctors at St. Jude.

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

Retrieved on: 
Wednesday, June 21, 2023
Partnership, University, College, Therapy, University of Tennessee Health Science Center, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmacy, The College of Medicine, SARS-CoV-2, UTHSC, United States Department of Defense, Cancer, National Cancer Institute, Research, Government, University of Florida College of Pharmacy, NCI, Distinguishing, Breast cancer, Pharmaceutical industry, Pathology, Verus Pharmaceuticals

MIAMI, FL, June 21, 2023 (GLOBE NEWSWIRE) -- The University of Tennessee Health Science Center (UTHSC), oncology drug discovery research partner to Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, has secured two additional grants to develop oncology therapeutics for indications of high unmet need. UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01). These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.

Key Points: 
  • UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01).
  • These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.
  • Validation of this research approach is reflected in peer-reviewed support from the U.S. government in the form of two awarded grants.
  • We are committed to collaborating with our clinical partner, Veru, who may ultimately pursue for late-stage clinical drug development.”

USDA Approves Novel Vaccine Against Wildlife Spread of the Bacterium Responsible for Lyme Disease

Retrieved on: 
Tuesday, May 9, 2023
Infection, Yale University, Disease, University, Lyme disease, University of Tennessee Health Science Center, Lyme, Management, Borrelia burgdorferi, Tick-Borne Disease Alliance, Connecticut Agricultural Experiment Station, Golf, CDC, Cary Institute of Ecosystem Studies, Notifiable disease, USDA, Risk, CAES, Safety, Vaccine, Pharmaceutical industry

MEMPHIS, Tenn., May 9, 2023 /PRNewswire/ -- US Biologic, Inc. , a leading global entity in the development, commercialization, and distribution of orally delivered vaccines, announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.

Key Points: 
  • MEMPHIS, Tenn., May 9, 2023 /PRNewswire/ -- US Biologic, Inc. , a leading global entity in the development, commercialization, and distribution of orally delivered vaccines, announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.
  • The only known vector is the blacklegged tick, which is infected primarily by feeding on small wildlife mammals, particularly white-footed mice.
  • The vaccine, called "Borrelia Burgdorferi Bacterin," is spray-coated onto pellets that the mice consume.
  • "Our team members, our leadership, and our partners are dedicated to disease prevention," says US Biologic Chief Executive Officer Mason Kauffman.